Our Resource Centre contains a unique database of reference papers, currently 50 articles and counting, to help you identify how the Stomacher® may be used for different applications and protocols.

Can't find what you're looking for? Call us for personal assistance, UK +44 (0) 1903 823 077, USA + 1 772 621 8220 or ASIA PACIFIC + 65 6519 2283.

 

Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits.

Stomacher® 80 used to process lung tissue in antifungal drug trial for Aspergillus fumigatus.The Stomacher® 80 blending action selected for extraction of fungal spores post drug exposure. Ravuconazole is a new antifungal triazole with broad-spectrum activity and a long half-life in plasma. The study focussed on the antifungal efficacy, safety, and pharmacokinetics of ravuconazole lysine phosphoester in escalating dosages for the treatment of invasive pulmonary aspergillosis due to Aspergillus fumigatus in persistently neutropenic rabbits. Survival throughout the entire study was achieved in 95% of RVC5-treated rabbits (P < 0.001), 85% of RVC10-treated rabbits (P < 0.001), and 50% of AMB-treated rabbits (P < 0.05) in comparison to none of the untreated controls. Ravuconazole showed linear plasma pharmacokinetics and a large volume of distribution while maintaining concentrations in plasma above the MIC throughout the dosing interval. There was no evidence of hepatotoxicity or nephrotoxicity among ravuconazole-treated animals. Intravenously administered ravuconazole lysine phosphoester showed dose-dependent efficacy and an excellent safety profile for the treatment of invasive pulmonary aspergillosis in persistently neutropenic rabbits.

clinical microbiology drug efficacy Aspergillus Fumigatus Stomacher 80